I agree and believe that is exactly what they are trying and should do. Leronlimab is a MOA drug, not specific to TNBC, breast, melanoma, etc.....but any and all cancers that express CCR5 on or around the tumor. This trial is designed to prove that. If it does, yes BTD should be requested for the expanded basket trial IND.